หน้าแรก
ค้นหา
Dr. Keith T. Flaherty on 3-Year Follow-up of COMBI-d in Metastatic Melanoma
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Keith T. Flaherty on 3-Year Follow-up of COMBI-d in Metastatic Melanoma
Dr. Keith T. Flaherty on the NEMO Trial in NRAS-Mutant Melanoma
Dr. Keith Flaherty Discusses Long-Term Data from the COLUMBUS Trial
Dr. Flaherty on Second-Line Therapy for BRAF-Mutant Melanoma
Dr. Flaherty Discusses the COLUMBUS Trial in Melanoma
Phase III COMBI-d Study of Dabrafenib and Trametinib in Patients With Melanoma
Dr. Keith Flaherty: Genetics of Cancer, Targeted Therapies, and Clinical Trials
Keith T. Flaherty, MD, Editor-in-Chief, Clinical Cancer Research
Dr. Nathan on 5-Year Survival Outcomes of COMBI-d and COMBI-v Trials in BRAF V600-Mutant Melanoma
Dr. Jason Luke Describes Results from the Phase III COMBI-d Trial
Phase 3 COMBI-d trial of dabrafenib plus trametinib in metastatic
#62–Keith Flaherty, M.D.: Deep dive into cancer—History, novel treatments, & the exciting future
Negative results of B-raf inhibitor therapy of melanoma not published
Immunotherapy in Advanced Melanoma
Leapfrog Moments in Cancer Therapies with Keith Flaherty, MD
Dr. Robert on Next Steps Following the Phase III COMBI-v Study in Melanoma
Recent Developments in Targeted Therapies for Melanoma
Dr. Robert on the Phase III COMBI-v Study in BRAF-Mutant Melanoma
Dr. Postow on FDA Approval of Adjuvant Dabrafenib Plus Trametinib in BRAF-Mutant Melanoma
BGB324 With Pembrolizumab or Dabrafenib/Trametinib in Melanoma
